Citations

Citations to this article as recorded by  

• Network pharmacology analysis and animal experiment validation of inflammation inhibition by Swertiamarin in treating Ulcerative colitis
  Tang Jiafeng, Wang Lijuan, Wei Lan, You Yiqing, Yang Shiyu, Zeng Tao, Dang Tingting, Sun Haoli, Li Xiaoshan, Zhang Yan
  Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(8): 10597.     CrossRef
• Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
  Sujia Liu, Yongle Liu, Shuhua Lai, Yingling Xie, Wenlong Xiu, Changyi Yang
  BMC Pediatrics.2024;[Epub]     CrossRef
• Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
  泊辛 陈
  Advances in Clinical Medicine.2024; 14(07): 1110.     CrossRef
• The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
  Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
  Intestinal Research.2021; 19(1): 62.     CrossRef
• The utility of faecal and urine biomarkers for small bowel diseases
  M.S. Ismail, Serhiy Semenov, Deirdre McNamara
  Current Opinion in Gastroenterology.2021; 37(3): 284.     CrossRef
• A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease
  Jong-Mi Lee, Joo Hee Jang, Ji Hyeong Ryu, Jaeeun Yoo, Bo-In Lee, Seung-Jun Kim, Eun-Jee Oh, Hsu-Heng Yen
  PLOS ONE.2021; 16(8): e0255974.     CrossRef
• Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
  Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
  Medicine.2021; 100(34): e27065.     CrossRef
• Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins
  Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang,
  Gastroenterology.2020; 158(3): 515.     CrossRef
• Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
  Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
  Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295.     CrossRef
• Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?
  Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan
  Expert Review of Gastroenterology & Hepatology.2019; 13(4): 319.     CrossRef
• Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
  Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
  Gastroenterology.2019; 157(4): 1032.     CrossRef
• Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
  Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke
  BMJ Open.2019; 9(3): e027428.     CrossRef
• Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes
  Tom Nilsen, Siri Helen Haugen, Anders Larsson
  Health Science Reports.2018;[Epub]     CrossRef
• Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
  Ji Young Chang, Jae Hee Cheon
  Gut and Liver.2018; 12(2): 117.     CrossRef
• Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease
  Cristina Verdejo, Daniel Hervías, Óscar Roncero, Ángel Arias, Abdelmouneim Bouhmidi, Rufo Lorente, Irina Salueña, Alfredo J. Lucendo
  European Journal of Gastroenterology & Hepatology.2018; 30(12): 1521.     CrossRef
• Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring
  Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong
  Intestinal Research.2018; 16(4): 546.     CrossRef
• Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
  Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
  The American Journal of the Medical Sciences.2017; 353(5): 439.     CrossRef
• Fecal biomarkers in inflammatory bowel disease: how, when and why?
  Paula Ministro, Diana Martins
  Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317.     CrossRef
• Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?
  Shu Chen Wei
  Intestinal Research.2016; 14(4): 293.     CrossRef